52 results about "Neuroglial cells" patented technology

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

The present invention relates to a forebrain assembloid that exhibits a maturity similar to that of the human brain, and a schizophrenia biomarker identified using the forebrain assembloid. More specifically, the present invention relates to: a method for preparing a forebrain assembloid; a forebrain assembloid having a single rosette structure that includes six cortical layers and cavities, the cortical layers including glial cells; a composition for diagnosing schizophrenia, comprising an agent for measuring the expression level of UCN, an agent for measuring the expression level of PTPRF, an agent for measuring the expression level of WNT11, and an agent for measuring the expression level of THBS4; and a kit comprising the composition for diagnosing schizophrenia.

Compositions, nucleic acid molecules, and methods for inducing retinal regeneration and reprogramming Muller glial cells (MGs) into retinal ganglion cells in a subject are described. The development of retina ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increases the MG neurogenesis capability induced by Ascl1. The combination of Ascl1, Pou4f2, and Islet1 stimulates the MG to produce bipolar cells and RGC-like neurons. Likewise, a transcription factor Onecut1, which is expressed in developing retinal cells but not expressed in MG, induces MG to produce RCG-like cells. Other transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. The MG-derived RGC can exhibit action potential in vivo, and exhibit chromatin characteristics similar to those of developing RGC.

To provide a drug having positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.SOLUTION: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons.SELECTED DRAWING: Figure 12

The present application relates to reducing the adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, astrocyte loss, or white matter loss, in the brain of a subject. The present application also relates to rejuvenating glial progenitor cells or their progeny, or enhancing the developmental potential of glial progenitor cells or their progeny.

The present application provides a mutant basic-helix-loop-helix (bHLH) transcription factor that comprises a mutation of one or more phosphoacceptor site for proline-directed serine-threonine kinases alone or together with a mutation in a conserved PKA site in the HLH domain, found in the corresponding wild-type bHLH transcription factor, and exhibits reduced phosphorylation by proline-directed serine-threonine kinases and PKA. Also provided are nucleic acids encoding the mutant bHLH transcription factor, and vectors comprising the encoding nucleic acids. Use of the mutant bHLH transcription factor or nucleic acid encoding the mutant bHLH transcription factor for therapeutic purposes can efficiently induce neuronal lineage conversion of glial cells, even in an inhibitory environment, and are useful in preventing or treating neurodegenerative diseases and disorders, and for treating CNS injuries. Further provided a use a ZBTB 18 transcription factor or a nucleic acid encoding the ZBTB 18 transcription factor for neuronal lineage conversion of glial cells.

The present invention relates to a forebrain assembloid that exhibits maturity similar to that of the human brain and expresses ChR2 to enable optogenetic analysis and, more specifically, to: a method for producing a forebrain assembloid that enables optogenetic analysis; a forebrain assembloid produced by the method; and a forebrain assembloid having a single rosette structure, comprising six cortical layers and cavities, wherein the cortical layers include glial cells and uniformly express ChR2.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

The invention belongs to the field of biological medicine, and particularly relates to a medicine for promoting microglial cell M2 type polarization and application of the medicine. The drug provided by the invention contains Densiflorol B. The drug provided by the invention has the advantages that the drug effect is good; the medicine can promote M2 type polarization of microglial cells, and has protection and repair effects on damaged nerves.

The invention belongs to the technical field of mesenchymal stem cells, and particularly relates to a preparation method of a Muc-MSC cell preparation of overexpression exosome binding peptide-NCS1 fusion protein. The method comprises the following steps: designing an exosome binding peptide sequence, constructing an exosome binding peptide-NCS1 fusion gene sequence, constructing a lentivirus for overexpressing an exosome binding peptide-NCS1 fusion protein, and constructing a muc-MSC for overexpressing the exosome binding peptide-NCS1 fusion protein. The Muc-MSC cell preparation of the overexpressed exosome binding peptide-NCS1 fusion protein, prepared by the invention, can transfer the fusion protein to target cells such as exosome, targeted neurons and glial cells, so that an endocannabinoid synthesis pathway is enhanced by the NCS1, the symptoms of the Parkinson's disease are relieved, and help is provided for future cell therapy of the Parkinson's disease.

The invention discloses application of ethyl caffeate in preparation of heart and nerve protection medicines, and belongs to the technical field of biological medicines. Models of rat embryo myocardial cell injury caused by oxygen-glucose deprivation and mouse microglial cell injury caused by lipopolysaccharide are respectively constructed, and related indexes such as inflammation, oxidative stress and cell apoptosis are evaluated; it is proved that ethyl caffeate has an obvious protection effect on ischemic and hypoxic myocardial cells and inflammation-damaged glial cells, and can be used for preparing heart and nerve protection drugs.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The invention relates to a cystamine derivative or a salt thereof and an application of the cystamine derivative or the salt in preparation of a medicine with an anti-oxidation effect. According to the application of the cystamine derivative or the salt of the cystamine derivative in preparation of the medicine with the anti-oxidation effect, the cystamine derivative has the structural characteristics shown in a formula (1), a formula (2) or a formula (3). The research finds that the cystamine derivative or the salt thereof with the structural general formula can exert a better antioxidant effect, can be used for preventing and treating or improving diseases related to oxidative stress, has a protection effect on neuroglial cells and nerve cells, and has the characteristics of high efficiency and safety. # imgabs0 #

Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.

The invention discloses a composition for enhancing memory and improving cognitive function and application. The composition disclosed by the invention comprises acanthopanax, ginseng, Chinese wolfberry fruits, gastrodia elata, spina date seeds, poria cocos, Chinese yams, lotus seeds, gordon euryale seeds, mulberries, longan pulp, fresh ginger, walnut powder, egg protein powder, blueberry powder, raspberry powder, pumpkin seed powder, oat powder, spirulina powder, dark chocolate powder, a vitamin B group compound, gamma-aminobutyric acid, galactooligosaccharide and citric acid. According to the invention, a multi-channel and multi-target collaborative network is constructed by taking acanthopanax senticosus as a core, through multiple channels such as nerve regeneration, energy metabolism, oxidative stress, signal transduction, endocrine regulation and the like, different nodes such as neurons, neuroglial cells, cerebrovascular endothelium and the like are targeted, the overall optimization of the memory function is realized on the system level, and the memory function is optimized. The core idea of systematic biology of overall regulation and control is reflected, and the composition prepared from the composition has the effects of improving memory, learning ability and cognitive ability.

The invention provides a method for in-vitro detection of exogenous gene expression activity of AAV virus in nerve cells and an evaluation system. The method comprises the following steps: infecting N2A cranial nerve tumor cells by using AAV carrying a neuron-specific promoter or a glial cell-specific promoter and a reporter gene driven by the neuron-specific promoter or the glial cell-specific promoter; and detecting the level of a reporter gene transcript or a protein expressed by the reporter gene in the infected N2A cranial nerve tumor cell so as to detect the activity of the AAV expressing the exogenous gene. According to the method disclosed by the invention, the target gene expression driven by the CamKII promoter of the AAV9 serotype is tested by utilizing the N2A cranial nerve tumor cells, the problem that a suitable cell model is lacked in the prior art is solved, and a new tool and a new method are provided for AAV activity test in neurobiology research.

This invention belongs to the field of biology and discloses a method for co-culturing enteric glial cells (EGCs) and intestinal organoids. Primary cultured and purified enteric glial cells are digested and seeded onto the membrane of a Transwell chamber. Intestinal organoids are placed in individual Matrigel drops in a co-culture plate. The Transwell chambers are placed in the co-culture plate, and growth medium is added to ensure free exchange of the growth medium through the Transwell membrane. The EGC-organoid co-culture system obtained based on this method provides a model for studying diarrhea and intestinal health in large mammals. It also lays the research foundation for developing innovative intervention strategies targeting the enteric nervous system and provides a research model for further exploring the regulatory roles of nutrients or related genes in intestinal health.

The invention discloses a dual-targeting viscosity detection near-infrared fluorescence / photoacoustic probe as well as preparation and application thereof, and a probe ER-V2 with viscosity specific recognition capability is successfully designed and synthesized by taking trimethylbenzoindole as a core. The probe ER-V2 is based on a hemicyanine donor-pi-receptor (D-pi-A) structure, a p-toluene sulfonamide part is used for targeting endoplasmic reticulum, and an N, N-dimethylaminophenyl part is used for A beta plaque binding, so that precise double targeting is realized. The extended pi conjugation provides near-infrared emission, enhances viscosity sensitivity by limiting intramolecular rotation, and produces a strong photoacoustic signal. In combination with high sensitivity of near-infrared fluorescence and strong penetrating power of a photoacoustic technology in tissues, the probe ER-V2 can penetrate a blood brain barrier, realizes real-time and high-sensitivity near-infrared fluorescence / photoacoustic imaging in neuroglial cells and the brain of a mouse with the Alzheimer's disease, and has important significance on early diagnosis of the Alzheimer's disease. The fluorescent probe is expected to become a useful fluorescent tool for researching Alzheimer's disease and endoplasmic reticulum related diseases in the future.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

Disclosed herein is a composition including a nucleoside-modified mRNA encapsulated in a lipid nanoparticle wherein the nucleoside-modified mRNA encodes IL10, IL-6, MIP1a, GDNF (glial cell line-derived neurotrophic factor), or a combination thereof. A method of treated spinal cord injury is also described.

The invention relates to a phenanthrene type norditerpenoid, a preparation method thereof and an application of the phenanthrene type norditerpenoid in a medicine for preventing and treating neuroinflammation in the technical field of biological medicines, and the phenanthrene type norditerpenoid is extracted from Leucodendron hainanense and is a norditerpenoid component with a gem-dimethyl 6 / 6 / 6 tricyclic phenanthrene type structure. The extraction method comprises the following steps: firstly, extracting a dried medicinal material of Hainan acalypha australis with ethanol with the mass concentration of 95%, and then filtering, concentrating under reduced pressure and drying to obtain a 95% ethanol extract; adding water to disperse, and sequentially extracting with petroleum ether, ethyl acetate and n-butyl alcohol to obtain extracts of corresponding parts; and finally, performing chromatographic separation and purification on the ethyl acetate part. The phenanthrene type norditerpenoid disclosed by the invention can be used for inhibiting the release of an inflammatory factor NO of BV-2 neural microglial cells; the invention has important significance on the development of drugs for treating neuroinflammation diseases.

Multispecific binding molecules having a first binding domain targeting a blood brain barrier target and a second binding domain targeting a neuron target, astrocyte target and / or glial cell target, and uses thereof in aiding the treatment of central nervous system diseases including neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's diseases, Progressive Supranuclear Palsy (PSP), Amyotrophic Lateral Sclerosis (ALS), Frontal Temporal Dementia (FTD), autism, catalepsy, encephalitis, migraine, and Tourette's.

The transdifferentiation of glial cells into neurons is useful for prevention or treatment of a disease associated with loss of function or death. The present disclosure relates to the field of biomedicines. More specifically, the present disclosure relates to use of a REST inhibitor in the treatment of a disease associated with loss of function or death of neurons. The present disclosure can effectively induce transdifferentiation of astrocytes into dopamine neurons by inhibiting the expression, content or activity of a gene of REST or an RNA thereof or an encoding protein thereof in astrocytes in the brain, and can effectively induce transdifferentiation of Müller glia (MG) into retinal ganglion cells (RGCs) or photoreceptor cells by inhibiting the expression, content or activity of the gene of REST or the RNA thereof or the encoding protein thereof in the retina, thereby preventing and / or treating the disease associated with loss of function or death of neurons.

The invention relates to in vivo methods and compositions for converting one cell type to another cell type. In particular, the invention relates to transdifferentiation of a cell to a photoreceptor cell, preferably a rod photoreceptor cell. In one aspect, the invention provides an in vivo method for reprogramming a source cell, the method comprising increasing the protein expression of one or more transcription factors, or biologically active fragments or variants thereof, in the source cell, wherein the source cell is reprogrammed to exhibit at least one characteristic of a target cell, wherein the source cell is a glial cell, the target cell is a photoreceptor cell; and the transcription factors are one or more of those selected from ASCLI, NEURODI, NRL, NR2E3, RAX, RORB, OTX2, CRX and PAX6.

The application discloses a Bifidobacterium longum subsp. longum strain for regulating intestinal homeostasis and relieving intractable constipation and an application thereof, and belongs to the field of microorganisms. The strain CCFM1319 provided by the application can shorten the time of the first black stool of intractable constipation mice, significantly enhance the colon peristalsis ability of the intractable constipation mice, increase the expression level of the characteristic marker of enteric glial cells in the colon tissue, repair the intestinal nerve damage caused by intractable constipation, reduce the expression level of inflammatory factors in the colon tissue of the intractable constipation mice, relieve the inflammation of the intestinal immune barrier, reduce the pathological damage of the colon tissue, increase the expression amount of the tight junction protein in the colon tissue, repair the damage of the intestinal mechanical barrier, avoid excessive water absorption, be beneficial to the excretion of feces, regulate the intestinal chemical barrier, improve the intestinal microecological imbalance, make the intestinal flora structure tend to be healthy, and repair the damage of the intestinal biological barrier, so as to play a role in comprehensively relieving intractable constipation.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

This application relates to cystamine derivatives or salts thereof and their use in the preparation of drugs with antioxidant effects. The use of the cystamine derivatives or salts thereof in the preparation of drugs with antioxidant effects, the cystamine derivatives having the structural characteristics shown in the following formula (1), formula (2) or formula (3). The present application has found that the cystamine derivatives or salts thereof having the general structural formula shown above can exert good antioxidant effects, can be used to prevent or improve diseases related to oxidative stress, and have a protective effect on glial cells and nerve cells, and are highly effective and safe. #imgabs0#

To provide a method of regenerating neurons and glia cell loss as a result of an insult from injury or disease.SOLUTION: This method comprises: a) providing a subject in need of regenerating neurons and glia cell loss; and b) administering to the subject cyclic Prolyl Glycine (cPG) or its analogues (cyclic(tri(Prolyl Glycine) or cyclic Glycyl-2-Allyl Proline, or cyclic Glycyl-Alkyl Proline or cyclic Glycyl-2-Methyl-Proline (cPMeG)) (collectively called a cPG compound), or a combination thereof, in an effective amount to regenerate new neurons and glia cells. Therein: the neurons are regenerated and the glia cell loss is regenerated in the subject; further the cPG compound serves as a neurogenesis agent in the central nervous system; and further the neurons and glia cell loss as a result of an insult from injury or disease are regenerated.SELECTED DRAWING: Figure 3

It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.